1. Targeting JAK-STAT signal transduction in IBD. Soendergaard C. et alPharmacology & Therapeutics 192(2018): 100-111

Antibody-based biological drugs were a significant advance for IBD treatments, but unfortunately a high percent of patients doesn’t respond well to this therapy highlighting the need for alternative therapies. Recent studies have shown the great potential of JAK inhibitors to face this unmet medical need.

Read this article for fuller information about the characteristics that make JAK inhibitors promising as innovative therapies, but also about the challenges for their delivery to the gut. Besides, this publication reviews existing clinical studies, currently available treatments and the different outlooks of IBD treatments.
Read more

2. Inhibition of Rho kinase protects against colitis in mice by attenuating intestinal epithelial barrier dysfunction via MLC and the NF-κB pathway. Zou Y. et al International Journal of Molecular Medicine 41 (2018): 430-438

The characteristic intestinal inflammation of IBD often results in a leaky intestinal epithelial barrier, compromising the capacity of this tissue to properly separate the inner and outer environments in the bowel.
This dysfunction is caused by an altered connection between the cells of the epithelium and thus the molecular mechanism responsible for this process are key therapeutic targets. In this context, recent studies have reported that the ROCK kinase appears to be involved in this process.

This article covers a new approach to treat IBD by targeting this kinase.Their results show that in models of mouse colitis the ROCK inhibition diminishes the inflammation and the intestinal permeability, which suggests a reduction of colitis too  Read more